中西医结合治疗围绝经期综合征40例被引量：1

40 Cases of Perimenopausal Syndrome Treated with Integration of Chinese and Western Medicine

下载PDF

导出

摘要目的:评价中西医结合方法治疗他莫昔芬引起的围绝经综合征的临床疗效。方法:80例他莫昔芬治疗1年以上、伴有明显的内分泌紊乱症状且评分>60分者为纳入对象,随机分为两组,对照组予以他莫昔芬口服,治疗组在对照组治疗基础上,加服疏肝宁心调阴阳方,两组均2个月为1疗程。治疗结束时,采用改良Kuppermann评分量表评价症状改善程度;同时采用KPS评分标准评价患者的生活质量。结果:治疗组在治疗后15 d开始KPS评分下降(P<0.05),对照组治疗结束时无明显改善。治疗组患者的围绝经期各个症状积分均有非常显著性差异(P<0.01),对照组患者的症状积分中,仅眩晕、骨关节痛、头痛及心悸症状有改善,治疗组各症状改善评分均明显优于对照组(P<0.01);治疗组患者KPS评分较治疗前有明显提高(P<0.05),对照组治疗后无变化(P>0.05),两组比较,治疗组较对照组有明显提高(P<0.05)。结论:中西医结合方法可以显著改善他莫昔芬引起的围绝经症状群,同时提高患者生活质量,有效缓解他莫西芬治疗乳腺癌引起的不良反应。 Objective：To evaluate the clinical effects of perimenopausal syndromes caused by tamoxifen treated with integrated Chinese medicine and western medicine. Methods：Eighty patients treated with tamoxifen for more than 1 year,with positive perimenopausal syndromes,with socre〉60,were included;the control group was given oral medication of tamoxifen and the treatment group was given oral administration of tamoxifen plus Sugan Ningxin Tiaoyinyang formula;both group were treated for 2 months. The therapeutical effects were evaluated with modified Kuppermann score sheet;and life quality of the patient was evaluated with Karnofsky performance status（KPS） score. Results：Fifteen days after treatment,the Kuppermann score began to degrease in the treatment group,whereas there was no obvious change in the control group. Compared to the control group, the Kuppermann scores degreased significantly with statistical differences（P〈0.05）. There were obvious changes of symptom scores in the treatment group （P〈0.01）, whereas in the control group,only scores of dizziness,arthralgia,headache and palpitation were decreased; score of each symptom in the treatment group was bettern that in the control group（P〈0.01） ;KPS scores in the treatment group were high compared to the pre-treatment（P〈0.05）,while there was no significant improvement in the control group（P〉0.05）; the effect of the treatment group was better than that in the control group. Conclusion： Integration of Chinese and western medicine can effectively reduce the perimenopausal symptoms caused by tamoxifen and improve the life qualities of such patients;besides,it can effectively relieve the side effect of tamoxifen during the treatment for breast cancer.

作者卞卫和张晓清李琳杨静应语姚昶

机构地区江苏省中医院乳腺外科南京中医药大学

出处《山东中医杂志》 2014年第5期381-383,共3页 Shandong Journal of Traditional Chinese Medicine

基金江苏省中医药局课题(编号:LZ11001)

关键词中西医结合疗法疏肝宁心方他莫昔芬围绝经期综合征 integration of Chinese and western medicine Shugan Ningxin formula tamoxifen perimenopausal syndromes

分类号 R275.12 [医药卫生—中医皮科]

引文网络
相关文献

参考文献2

1黄平,王晓稼.绝经前女性乳腺癌辅助内分泌治疗选择策略[J].肿瘤防治研究,2012,39(6):623-626. 被引量：6
2曹杰,赵纯全.莉芙敏治疗妇女围绝经期综合征的疗效研究[J].临床合理用药杂志,2012,5(9):17-20. 被引量：10

二级参考文献24

1Early Breast Cancer Trialists' Collaborative Group(EBCTCG), Da- vies C,Godwin J,et al. Relevance of breast cancer hormone re- ceptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials [J]. Lancet, 2011,378(9793) :771-84.
2Goldhirsch A,Wood WC,Coates AS, et al. Strategies for sub- types-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J]. Ann Oncol,20]l ,22 (8) : 1736-47.
3Partridge AH. Ovarian suppression for prevention of premature menopause and infertility: empty promise or effective therapy? [J]. J Clin Oncol,2012,30(5):479-81.
4Jonat W,Kaufmann M,Sauerbrei W,et al. Goserelin versus cy- clophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study[J]. J Clin 0ncol,2002,20(24), 4628-35.
5Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonado- tropin-releasing hormone analogue triptorelin on the occur- rence of chemotherapy-induced early menopause in premenopa- usal women with breast cancer~ a randomized trial[J]. JAMA,2011,306(3) :269-76.
6Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast caucer[J], d Clin Oneol, 2012,31) ( 5 ) :533 8.
7Pfeiler G,Konigsberg R,Fesl C,et al. Impact of body mass in- dex on the efficacy of endocrine therapy in premenopausal pa- tients with breast cancer: an analysis of the prospective ABC- SG-12 trial[J]. J Clin Oncol,2011,29(19) :2653-9.
8International Breast Cancer Study Group(IBCSG) ,Castiglione- Gertsch M,O' Neill A, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node negative breast cancer: a randomized trial[J]. J Natl Cancer Inst,2003,95(24) : 1833-46.
9Klijn JG, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer.-a meta-analysis of four randomized trials[J]. J Clin On- col,2001,19(2) :343-53.
10Davidson NE, O'Neill AM, Vukov AM, et al. Chemoendoerine therapy for premenopausal women with axillary lymph node positive, steroid hormone receptor-positive breast cancer: re suits from INT 0101(E5188) [J].J Clin Oneol,2005,23(25) : 5973-82.